Dramatic response of malignant craniopharyngioma to cis-platin-based chemotherapy. Should craniopharyngioma be considered as a suprasellar 'germ cell' tumour?
The case is described of a 21-year-old woman, who developed a malignant tumour arising from a craniopharyngioma 14 years after the original diagnosis. The remarkable response of this malignant tumour ex-craniopharyngioma to cis-platin based chemotherapy, together with other midline tumour characteristics of craniopharyngioma, raise the question as to whether craniopharyngioma should any longer be separately considered from suprasellar germ cell tumour. This subject is discussed.
Plowman
P N
PN
Department of Clinical Oncology, St Bartholomew's Hospital, London, UK.
Besser
G M
GM
Shipley
J
J
Summersgill
B
B
Geddes
J
J
Afshar
F
F
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002869:Chromosome Aberrations; D002945:Cisplatin / Q000008:administration & dosage; D003397:Craniopharyngioma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
D005047:Etoposide; D002945:Cisplatin